Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Ensuring The Future Of The Experienced Investigator Is Ingrained In Good Clinical Practice Guidance

3
January 2024

The ICH Expert Working Group has been revising the Good Clinical Practice (GCP) guideline, ICH E6 (GCP) R3.

View Article

Powering STEM Dreams: Snowsfield's Exciting Tour of Richmond Pharmacology

18
December 2023

Richmond Pharmacology recently welcomed STEM leaders from Snowsfield Primary School, marking a follow-up to our donation of STEM books for their library.

View Article

Characterisation of the Cardiovascular Effects of a Meal: QTcF Assessment and Further Insights into the Physiological Effects

4
December 2023

Groundbreaking research paper authored by Dr. Georg Ferber, Dr. Dilshat Djumanov, Dr. Ulrike Lorch, Dr. Edward Jackson, Dr. Joao Almeida Melo, Mr. James Rickard, and Dr. Jorg Taubel. 

View Article

Richmond Pharmacology becomes Richmond in Brand Refresh

1
December 2023

Refreshed brand reflects company’s growth over 22 years and renewed commitment to turning hope into reality for patients.

View Article

Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS-986231)

21
November 2023

For patients with heart failure and congestion, vasodilation with agents such as cimlanod reduces the response to diuretic agents, which may offset any benefit from acute reductions in cardiac preload and afterload.

View Article

Richmond Pharmacology at the Forefront of Groundbreaking Gene-Editing Clinical Trials

16
November 2023

Richmond Pharmacology proudly announces its pivotal role in a ground breaking gene-editing clinical trial for heart disease.

View Article

Latest news

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event